Developing a vaccine to trigger strong immune responses against the flu virus
Triggering germline-encoded broadly neutralizing antibody responses against influenza virus
This study is looking at how we can help the immune system make better antibodies to fight off different types of the flu virus, using special mouse models that act like humans, to find ways to improve flu vaccines for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10663939 on NIH RePORTER |
What this research studies
This research focuses on understanding how the immune system can be trained to produce broadly neutralizing antibodies against the influenza virus. Using specially designed mouse models that mimic human immune responses, the researchers will explore how to stimulate specific B cell lineages that are capable of generating effective antibodies against various strains of the flu. By genetically manipulating these models, they aim to identify the best ways to enhance the immune response to flu vaccines, potentially leading to more effective vaccination strategies.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research would include individuals at high risk for influenza complications, such as the elderly, young children, and those with compromised immune systems.
Not a fit: Patients who are not at risk for influenza or those who have already been vaccinated with existing flu vaccines may not receive significant benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a more effective flu vaccine that provides broader and longer-lasting protection against multiple strains of the virus.
How similar studies have performed: Previous research has shown promise in using similar approaches to enhance immune responses, indicating potential for success in this novel application.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Lingwood, Daniel — Massachusetts General Hospital
- Study coordinator: Lingwood, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.